GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council […]